(Sharecast News) - Eli Lilly said on Tuesday that it has agreed to buy Centessa Pharmaceuticals, a clinical-stage company developing a new class of medicines for the treatment of excessive daytime sleepiness, for up to $7.8bn.
Centessa is developing a new class of potential therapies within its orexin receptor 2 (OX2R)...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE